Before starting a medication, PGx looks at how different people's drug metabolizing enzymes are from one another. As a result, adverse events caused by toxicity and the metabolism of the patient can be avoided. This paper looks at two different uses: a genetic test of the CYP 2C9 enzyme and the Thiopurine methyltransferase gene before beginning mercaptopurine drug therapy and before administering the anticoagulant warfarin. According to the biomedical literature, barriers to PGx have limited clinician experience. A lack of prospective clinical trials, legacy business models between the pharmaceutical industry and physicians, inadequate regulatory oversight, payer reimbursement practices, and physician habits are among these. PGx is unlikely to see widespread use until these issues are addressed. The most significant obstacles to clinician adoption are unproven utility and ingrained business models.
Published Date: 2023-06-28; Received Date: 2023-07-01
